Evidence map›Paper›PMID 42849917›Full record

ArticleJournal for immunotherapy of cancer2026

Cell-delivered CD3×CD19 T-cell engager by STAb-T19 cells mediates leukemia clearance with limited systemic exposure.

Laura Sanz-Ortega, Elena Barba-Sarasúa, Ivana Zagorac, Antonio Tapia-Galisteo, Lucía Rivas-Gómez, Noelia López, Belén Blanco, Carolina Pola, Luis Alvarez-Vallina

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laura Sanz-OrtegaCNIO-HMRIB Cancer Immunotherapy Clinical Reserach Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain lasanz@ext.cnio.es lalvarezv@ext.cnio.es.ORCID http://orcid.org/0000-0003-0413-6311
Elena Barba-SarasúaCNIO-HMRIB Cancer Immunotherapy Clinical Reserach Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0001-9164-3551
Ivana ZagoracCNIO-HMRIB Cancer Immunotherapy Clinical Reserach Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Antonio Tapia-GalisteoCNIO-HMRIB Cancer Immunotherapy Clinical Reserach Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Lucía Rivas-GómezCNIO-HMRIB Cancer Immunotherapy Clinical Reserach Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Noelia LópezSTAb Therapeutics, Madrid, Spain.
Belén BlancoDepartment of Advanced Therapy Drug Development, Instituto de Salud Carlos III, Madrid, Spain.
Carolina PolaSTAb Therapeutics, Madrid, Spain.
Luis Alvarez-VallinaCNIO-HMRIB Cancer Immunotherapy Clinical Reserach Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain lasanz@ext.cnio.es lalvarezv@ext.cnio.es.ORCID http://orcid.org/0000-0003-3053-6757

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bispecific T cell engager - BiTEBispecific T cell engager - TCEImmunotherapyLeukemiaPharmacodynamics - PDPharmacokinetics - PK

Identifiers

PMID42849917
PMCPMC13656137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.